1. Jorgensen JH, Pfaller MA, editors. 2015. Manual of clinical microbiology. 11th ed. ASM Press;Washington: p. 967–93.
2. Lee SA, Liu F, Riordan SM, Lee CS, Zhang L. 2019; Global investigations of
Fusobacterium nucleatum in human colorectal cancer. Front Oncol. 9:566. DOI:
10.3389/fonc.2019.00566. PMID:
31334107. PMCID:
PMC6618585.

3. Kristensen LH, Prag J. 2008; Localised
Fusobacterium necrophorum infections: a prospective laboratory-based Danish study. Eur J Clin Microbiol Infect Dis. 27:733–9. DOI:
10.1007/s10096-008-0497-3. PMID:
18340470.
4. Johannesen KM, Bødtger U, Heltberg O. 2014; Lemierrés syndrome: the forgotten disease. J Thromb Thrombolysis. 37:246–8. DOI:
10.1007/s11239-013-0931-y. PMID:
23686643.
5. Kristensen LH, Jensen A, Prag J. 2009; Fusobacterium necrophorum: from tonsillitis to Lemierrés syndrome. Ugeskr Laeger. 171:987–90.
6. Bolstad AI, Jensen HB, Bakken V. 1996; Taxonomy, biology, and periodontal aspects of
Fusobacterium nucleatum. Clin Microbiol Rev. 9:55–71. DOI:
10.1128/CMR.9.1.55. PMID:
8665477. PMCID:
PMC172882.
7. Han YW, Fardini Y, Chen C, Iacampo KG, Peraino VA, Shamonki JM, et al. 2010; Term stillbirth caused by oral
Fusobacterium nucleatum. Obstet Gynecol. 115:442–5. DOI:
10.1097/AOG.0b013e3181cb9955. PMID:
20093874. PMCID:
PMC3004155.
8. Goldberg EA, Venkat-Ramani T, Hewit M, Bonilla HF. 2013; Epidemiology and clinical outcomes of patients with
Fusobacterium bacteraemia. Epidemiol Infect. 141:325–9. DOI:
10.1017/S0950268812000660. PMID:
22717143.
10. Castellarin M, Warren RL, Freeman JD, Dreolini L, Krzywinski M, Strauss J, et al. 2012;
Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res. 22:299–306. DOI:
10.1101/gr.126516.111. PMID:
22009989. PMCID:
PMC3266037.
11. Ohkusa T, Yoshida T, Sato N, Watanabe S, Tajiri H, Okayasu I. 2009; Commensal bacteria can enter colonic epithelial cells and induce proinflammatory cytokine secretion: a possible pathogenic mechanism of ulcerative colitis. J Med Microbiol. 58:535–45. DOI:
10.1099/jmm.0.005801-0. PMID:
19369513. PMCID:
PMC2887547.

12. CLSI. 2018. Methods for antimicrobial susceptibility testing of anaerobic bacteria. Approved standard. CLSI M11-A9. 9th ed. Clinical and Laboratory Standards Institute;Wayne, PA:
13. Shilnikova II, Dmitrieva NV. 2015; Evaluation of antibiotic susceptibility of Bacteroides, Prevotella and
Fusobacterium species isolated from patients of the N. N. Blokhin Cancer Research Center, Moscow, Russia. Anaerobe. 31:15–8. DOI:
10.1016/j.anaerobe.2014.08.003. PMID:
25157873.
14. Brook I, Wexler HM, Goldstein EJ. 2013; Antianaerobic antimicrobials: spectrum and susceptibility testing. Clin Microbiol Rev. 26:526–46. DOI:
10.1128/CMR.00086-12. PMID:
23824372. PMCID:
PMC3719496.

15. Aldridge KE, Ashcraft D, Cambre K, Pierson CL, Jenkins SG, Rosenblatt JE. 2001; Multicenter survey of the changing in vitro antimicrobial susceptibilities of clinical isolates of
Bacteroides fragilis group, Prevotella,
Fusobacterium, Porphyromonas, and Peptostreptococcus species. Antimicrob Agents Chemother. 45:1238–43. DOI:
10.1128/AAC.45.4.1238-1243.2001. PMID:
11257040. PMCID:
PMC90449.
16. Teng LJ, Hsueh PR, Tsai JC, Liaw SJ, Ho SW, Luh KT. 2002; High incidence of cefoxitin and clindamycin resistance among anaerobes in Taiwan. Antimicrob Agents Chemother. 46:2908–13. DOI:
10.1128/AAC.46.9.2908-2913.2002. PMID:
12183246. PMCID:
PMC127412.

17. Brazier JS, Goldstein EJ, Citron DM, Ostovari MI. 1990; Fastidious anaerobe agar compared with Wilkins-Chalgren agar, brain heart infusion agar, and brucella agar for susceptibility testing of
Fusobacterium species. Antimicrob Agents Chemother. 34:2280–2. DOI:
10.1128/AAC.34.11.2280. PMID:
2073122. PMCID:
PMC172040.
18. Marchand-Austin A, Rawte P, Toye B, Jamieson FB, Farrell DJ, Patel SN. 2014; Antimicrobial susceptibility of clinical isolates of anaerobic bacteria in Ontario, 2010-2011. Anaerobe. 28:120–5. DOI:
10.1016/j.anaerobe.2014.05.015. PMID:
24923267.

19. Appelbaum PC, Spangler SK, Jacobs MR. 1990; Beta-lactamase production and susceptibilities to amoxicillin, amoxicillin-clavulanate, ticarcillin, ticarcillin-clavulanate, cefoxitin, imipenem, and metronidazole of 320 non-
Bacteroides fragilis Bacteroides isolates and 129 fusobacteria from 28 U.S. centers. Antimicrob Agents Chemother. 34:1546–50. DOI:
10.1128/AAC.34.8.1546. PMID:
2221864. PMCID:
PMC171870.
20. CLSI. 2020. Performance standards for antimicrobial susceptibility testing. Approved standard. CLSI M100. 30th ed. Clinical and Laboratory Standards Institute;Wayne, PA:
21. Citron DM. 2002; Update on the taxonomy and clinical aspects of the genus
Fusobacterium. Clin Infect Dis. 35(S1):S22–7. DOI:
10.1086/341916. PMID:
12173104.
22. Kostic AD, Gevers D, Pedamallu CS, Michaud M, Duke F, Earl AM, et al. 2012; Genomic analysis identifies association of
Fusobacterium with colorectal carcinoma. Genome Res. 22:292–8. DOI:
10.1101/gr.126573.111. PMID:
22009990. PMCID:
PMC3266036.
23. Pett E, Saeed K. 2014; Dryden M.
Fusobacterium species infections: clinical spectrum and outcomes at a district general hospital. Infection. 42:363–70. DOI:
10.1007/s15010-013-0564-2. PMID:
24326987.
24. Epaulard O, Brion JP, Stahl JP, Colombe B, Maurin M. 2006; The changing pattern of
Fusobacterium infections in humans: recent experience with
Fusobacterium bacteraemia. Clin Microbiol Infect. 12:178–81. DOI:
10.1111/j.1469-0691.2005.01328.x. PMID:
16441457.
25. Afra K, Laupland K, Leal J, Lloyd T, Gregson D. 2013; Incidence, risk factors, and outcomes of
Fusobacterium species bacteremia. BMC Infect Dis. 13:264. DOI:
10.1186/1471-2334-13-264. PMID:
23734900. PMCID:
PMC3679863.

26. Nohrström E, Mattila T, Pettilä V, Kuusela P, Carlson P, Kentala E, et al. 2011; Clinical spectrum of bacteraemic
Fusobacterium infections: from septic shock to nosocomial bacteraemia. Scand J Infect Dis. 43:463–70. DOI:
10.3109/00365548.2011.565071. PMID:
21391770.
27. Candoni A, Filì C, Trevisan R, Silvestri F, Fanin R. 2003;
Fusobacterium nucleatum: a rare cause of bacteremia in neutropenic patients with leukemia and lymphoma. Clin Microbiol Infect. 9:1112–5. DOI:
10.1046/j.1469-0691.2003.00717.x. PMID:
14616727.
28. Kwong TNY, Wang X, Nakatsu G, Chow TC, Tipoe T, Dai RZW, et al. 2018; Association between bacteremia from specific microbes and subsequent diagnosis of colorectal cancer. Gastroenterology. 155:383–90.e8. DOI:
10.1053/j.gastro.2018.04.028. PMID:
29729257.

31. Johannesen KM, Kolekar SB, Greve N, Nielsen XC, Barfod TS, Bodtger U. 2019; Differences in mortality in
Fusobacterium necrophorum and
Fusobacterium nucleatum infections detected by culture and 16S rRNA gene sequencing. Eur J Clin Microbiol Infect Dis. 38:75–80. DOI:
10.1007/s10096-018-3394-4. PMID:
30374684.
32. Yang CC, Ye JJ, Hsu PC, Chang HJ, Cheng CW, Leu HS, et al. 2011; Characteristics and outcomes of
Fusobacterium nucleatum bacteremia-a 6-year experience at a tertiary care hospital in northern Taiwan. Diagn Microbiol Infect Dis. 70:167–74. DOI:
10.1016/j.diagmicrobio.2010.12.017. PMID:
21596220.
33. Goldstein EJC, Citron DM. 2011; Resistance trends in antimicrobial susceptibility of anaerobic bacteria, Part II. Clin Microbiol Newsl. 33:9–15. DOI:
10.1016/j.clinmicnews.2010.12.002.

34. Byun JH, Kim M, Lee Y, Lee K, Chong Y. 2019; Antimicrobial susceptibility patterns of anaerobic bacterial clinical isolates from 2014 to 2016, including recently named or renamed species. Ann Lab Med. 39:190–9. DOI:
10.3343/alm.2019.39.2.190. PMID:
30430782. PMCID:
PMC6240532.

35. Ng LS, Kwang LL, Rao S, Tan TY. 2015; Anaerobic bacteraemia revisited: species and susceptibilities. Ann Acad Med Singap. 44:13–8. PMID:
25703492.
36. Conrads G, Citron DM, Goldstein EJ. 2005; Genetic determinant of intrinsic quinolone resistance in
Fusobacterium canifelinum. Antimicrob Agents Chemother. 49:434–7. DOI:
10.1128/AAC.49.1.434-437.2005. PMID:
15616329. PMCID:
PMC538909.